MarketFriction

Syschem (India) Ltd

BSE 531173 · Pharmaceuticals
₹34.80 -1.89%
BSE close2026-10-01
Market cap₹194 Cr.
P/E31.6

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales37.1143.7474.7187.5347.5277.76118.87109.32103.60141.50219.35109.21
Expenses35.2642.6673.0986.7247.4576.56116.97106.86100.30135.54209.98108.67
Operating Profit1.851.081.620.810.071.201.902.463.305.969.370.54
OPM %4.99%2.47%2.17%0.93%0.15%1.54%1.60%2.25%3.19%4.21%4.27%0.49%
Other Income0.000.010.150.010.000.020.020.010.010.000.000.05
Interest0.030.110.010.000.030.040.000.040.010.172.040.49
Depreciation0.700.740.670.680.680.680.910.760.760.821.731.56
Profit before tax1.120.241.090.14-0.640.501.011.672.544.975.60-1.46
Tax %0.00%0.00%123.85%0.00%0.00%0.00%54.46%0.00%25.59%15.90%68.93%15.07%
Net Profit1.120.23-0.260.14-0.640.500.461.671.904.171.74-1.67
EPS in Rs0.280.06-0.070.04-0.160.130.110.380.440.960.36-0.34
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales4136793776859114199332574574
Expenses5126389777358105192328553554
Operating Profit-1034-0-519742119
OPM %-24%0.4%4.5%4.4%-0.1%-7%0.9%8%3.5%1.2%3.7%3.3%
Other Income0-0-0-00-0000000
Interest000000000023
Depreciation222222333345
Profit before tax-3-212-2-7-26411512
Tax %-27%-30%43%50%-16%-24%-22%27%33%54%26%
Net Profit-2-101-2-6-2530116
EPS in Rs-1.13-0.750.170.32-0.79-2.07-0.591.130.690.112.231.42
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth66%53%72%62%
Compounded Profit Growth21%32%34%209%
Stock Price CAGR21%33%-14%-35%
Return on Equity4%7%6%10%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital161616161919222332404449
Reserves-6-8-10-8-8-10-15-16-10174873
Borrowings2827222016171622000
Other Liabilities131216293536555169107126169
Total Liabilities514744586262776093164217292
Fixed Assets343230292728303231315368
CWIP111001100400
Investments000000000000
Other Assets161514283534462862129164224
Total Assets514744586262776093164217292
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1060-2341-8-26-108
Cash from Investing Activity00002-4-4-1-2-6-22-20
Cash from Financing Activity-2-1-7-0-0-0-0-011323418
Net Cash Flow-10-000-0-001-026
Free Cash Flow106-1-20-1-2-10-32-32-11
CFO/OP-56%-53%12,760%9%-24%-3,456%-40%107%-79%-348%-238%54%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days18727212447214731211351269992
Inventory Days22886818280104110199152611078141
Days Payable290870424151131175221186158198143112
Cash Conversion Cycle124271-119-24-7-199-1438343621
Working Capital Days-139-564-319-50-20-36-1-1548543929
ROCE %-11%-8%-6%3%7%-8%-29%-12%38%11%1%16%
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Jul 2026
Promoters53.89%53.89%53.89%53.17%53.17%57.02%56.71%56.71%56.71%60.86%60.15%63.38%
DIIs0.14%0.25%0.25%0.20%0.20%0.18%0.18%0.18%0.18%0.16%0.16%0.15%
Public45.97%45.86%45.87%46.63%46.63%42.79%43.11%43.11%43.11%38.97%39.70%36.47%
No. of Shareholders12,57113,94213,31013,30513,44513,22312,90613,27312,83612,85512,80912,825

Fundamentals

Market Cap₹ 194 Cr.
Current Price₹ 36.1
Stock P/E31.6
Book Value₹ 25.0
ROCE15.9 %
ROE10.2 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)62%
Compounded Profit Growth (TTM)209%
Standalone figures.
Valuation
Market capRs 171 Cr
Enterprise valueRs 162 Cr
P/E (TTM)27.78x
Price to book1.39x
Price to sales0.30x
EV / EBITDA8.40x
EV / EBIT11.25x
EV / sales0.28x
Price to cash flow22.47x
Earnings yield3.60%
P/E, 3-year average150.38x
P/B, 3-year average2.53x
P/E, 5-year average120.55x
P/B, 5-year average3.49x
Profitability
Operating margin (excl. other income)3.68%
Operating margin (incl. other income)3.68%
EBITDA margin3.35%
Pre-tax margin2.03%
Net profit margin1.07%
Net margin, latest quarter-1.53%
ROE10.23%
ROCE15.93%
ROA4.29%
ROE, 3-year average5.94%
ROCE, 3-year average9.37%
ROA, 3-year average2.23%
ROE, 5-year average4.50%
ROCE, 5-year average10.78%
ROA, 5-year average2.02%
ROIC (approx.)9.36%
Tax rate26.10%
Other income / net worth0.02%
Growth
Sales growth (latest year)72.99%
Profit growth (latest year)2276.09%
Sales CAGR, 3 years71.59%
Sales CAGR, 5 years52.98%
Profit CAGR, 3 years34.32%
Sales growth QoQ-50.21%
Profit growth QoQ-195.98%
Sales growth YoY (latest quarter)-0.10%
Profit growth YoY (latest quarter)-200.00%
Per share
EPS (TTM)Rs 1.25
EPS (latest year)Rs 2.23
EPS (latest quarter)Rs -0.34
EPS, 3-year averageRs 1.01
EPS, 5-year averageRs 0.74
Book value per shareRs 24.98
Sales per shareRs 117.04
Cash flow per shareRs 1.55
Free cash flow per shareRs -2.24
Efficiency
Asset turnover1.97x
Fixed asset turnover8.49x
Inventory turnover9.17x
Inventory days40 days
Debtor days92 days
Debtors turnover3.97x
Creditor days112 days
Cash conversion cycle21 days
Working capital days29 days
Leverage
Total debtRs 0 Cr
Cash and bankRs 9 Cr
Net debtRs -9 Cr
Debt to equity0.00x
Net debt / EBITDA-0.47x
Interest coverage5.30x
Owners' fund to total sources41.97%
Debt to assets0.14%
Cash flow
Cash from Operating Activity (latest year)Rs 8 Cr
Cash from Investing Activity (latest year)Rs -20 Cr
Cash from Financing Activity (latest year)Rs 18 Cr
Net Cash Flow (latest year)Rs 6 Cr
Free cash flow (latest year)Rs -11 Cr
Cash from ops / profit, 5 years-2.06x
Sales to cash flow75.60x
Statement figures
Net sales (TTM)Rs 574 Cr
Net sales (latest year)Rs 574 Cr
Sales (latest quarter)Rs 109 Cr
Operating profit excl. other income (latest year)Rs 21 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 19 Cr
PBDT (TTM)Rs 17 Cr
Profit before tax (TTM)Rs 12 Cr
Tax (latest year)Rs 4 Cr
Net profit (TTM)Rs 6 Cr
Net profit (latest year)Rs 11 Cr
Net profit (latest quarter)Rs -2 Cr
Depreciation (TTM)Rs 5 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 3 Cr
Cost of goods sold (latest year)Rs 534 Cr
Total expenditure (latest year)Rs 553 Cr
Total income (latest year)Rs 574 Cr
Share capitalRs 49 Cr
ReservesRs 73 Cr
Shareholders' fundsRs 122 Cr
Total assetsRs 292 Cr
Net blockRs 68 Cr
ReceivablesRs 144 Cr
InventoryRs 58 Cr
Other liabilitiesRs 169 Cr
Shares outstanding (crore)4.90
Ownership
Promoter holding63.38% (+6.67 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 27.8 is at the 8th percentile of its own 4.9-year range (median 55.4, low 20.9, high 151.1).
P/B 1.39 is at the 1th percentile (median 5.31).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
Period531173Nifty 50Difference
1 week-5.2%-2.8% -2.4 pts
1 month+9.3%-6.8% +16.1 pts
3 months-14.0%-7.6% -6.4 pts
3 years-39.3%+14.2% -53.5 pts
5 years+294.1%+27.9% +266.2 pts

Red flags

F-score 5 of 8
explainWeak cash conversion Cash from operations was -199% of net profit over the last 3 years
lookShare dilution Share count up 13% in a year, 23% in three
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹109 Cr -0.1% vs Jun 2025. Net loss ₹2 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Syschem (India) Ltd?

Syschem (India) Ltd (531173) has a market capitalisation of Rs 194 Cr. at the 2026-10-01 close.

What is the P/E ratio of Syschem (India) Ltd?

Syschem (India) Ltd trades at a P/E of 31.6 on trailing twelve-month profit, at the 2026-10-01 close.

What were Syschem (India) Ltd's latest quarterly results?

In the Jun 2026 quarter, Syschem (India) Ltd sales was Rs 109 Cr (-0.1% vs Jun 2025) with a net loss of Rs 2 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03